Facebook
Twitter
Telegram
Report an ErrorSupernus Pharmaceuticals Financial Ratios 2011-2024 | SUPN
Annual Financial Ratios Supernus Pharmaceuticals
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
32.7 | 30.7 | 12.2 | 10.9 | 17.4 | 35.7 | 13.8 | 38.4 | 18.1 | -3.4 | -2.9 | - |
P/S |
3.0 | 2.8 | 3.0 | 3.1 | 4.7 | 6.8 | 5.9 | 3.7 | 2.9 | 25.9 | 90.7 | - |
EPS |
1.1 | 1.0 | 2.4 | 2.2 | 2.1 | 1.1 | 1.8 | 0.3 | -0.3 | -2.9 | -2.7 | 31.4 |
EV (Enterprise Value) |
2.71 B | 2.31 B | 2.02 B | 1.61 B | 2.26 B | 2.1 B | 1.31 B | 575 M | 389 M | 356 M | 130 M | -4.26 M |
EBITDA per Share |
2.45 | 2.23 | 3.65 | 2.96 | 2.91 | 2.12 | 1.14 | 0.391 | 0.595 | -1.92 | -2.37 | - |
EV/EBITDA |
19.1 | 8.5 | 9.0 | 13.6 | 18.0 | 21.1 | 27.5 | 13.9 | -5.1 | -2.8 | - | |
PEG |
4.93 | 1.41 | 0.18 | 7.72 | 0.2 | -0.92 | 0.03 | -1.06 | 0.16 | 0.51 | 0.02 | - |
P/B |
2.2 | 2.0 | 2.1 | 2.1 | 4.3 | 7.6 | 6.6 | 4.5 | 5.0 | 9.3 | 2.3 | - |
P/CF |
17.0 | 12.9 | 11.2 | 8.8 | 15.1 | 18.1 | 19.3 | 17.9 | 50.3 | -5.2 | -2.8 | - |
ROE % |
6.85 | 6.55 | 17.04 | 18.99 | 24.50 | 21.42 | 47.57 | 11.79 | 27.85 | -275.74 | -80.40 | - |
ROA % |
3.57 | 3.16 | 8.44 | 9.74 | 11.35 | 13.50 | 29.47 | 7.43 | 14.45 | -83.13 | -49.24 | - |
ROCE % |
5.20 | 10.54 | 23.32 | 14.86 | 17.69 | 33.02 | 23.69 | 13.32 | 22.02 | -73.20 | -59.39 | - |
Current Ratio |
2.1 | 1.9 | 2.0 | 2.9 | 3.1 | 1.9 | 1.9 | 1.9 | 4.0 | 3.7 | 4.0 | - |
DSO |
86.0 | 91.2 | 80.0 | 81.2 | 91.9 | 79.2 | 70.5 | 65.5 | 51.6 | 168.2 | 166.5 | - |
DIO |
371.4 | 326.5 | 260.8 | 583.4 | 609.9 | 391.1 | 511.6 | 545.4 | 852.0 | 2364.6 | - | - |
DPO |
41.6 | 37.6 | 56.7 | 222.2 | 75.9 | 164.2 | 245.3 | 186.9 | 118.1 | 6054.9 | - | - |
Operating Cycle |
457.4 | 417.7 | 340.8 | 664.5 | 701.8 | 470.3 | 582.1 | 610.9 | 903.7 | 2532.7 | - | - |
Cash Conversion Cycle |
415.8 | 380.1 | 284.1 | 442.4 | 625.8 | 306.1 | 336.8 | 424.0 | 785.6 | -3522.2 | - | - |
All numbers in USD currency
Quarterly Financial Ratios Supernus Pharmaceuticals
| 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
- | - | -0.29 | -0.02 | 0.31 | - | 0.03 | 0.15 | 0.48 | - | 0.41 | 0.45 | 0.11 | - | 0.76 | 0.66 | 0.41 | 0.63 | 0.55 | 0.62 | 0.35 | 0.5 | 0.54 | 0.59 | 0.51 | 0.27 | 0.31 | 0.34 | 0.21 | 0.29 | 1.25 | 0.21 | 0.1 | 0.14 | 0.08 | 0.05 | 0.02 | 0.09 | -0.06 | 0.08 | -0.38 | -0.65 | -0.78 | -0.89 | -0.6 | -0.51 | -0.55 | -0.61 | -6.05 | 2.88 | -6.64 | -5.17 | -7.48 |
EBITDA per Share |
0.32 | - | 0.16 | -0.31 | 0.47 | - | -0.01 | 0.23 | 0.44 | - | 0.99 | 0.89 | 0.37 | - | 1.31 | 0.96 | 0.59 | 0.78 | 0.85 | 0.88 | 0.52 | 0.76 | 0.82 | 0.76 | 0.64 | 0.67 | 0.56 | 0.56 | 0.35 | 0.33 | 0.44 | 0.26 | 0.14 | - | 0.12 | 0.09 | 0.1 | - | - | 0.1 | -0.32 | - | -0.54 | -0.49 | -0.57 | - | -0.48 | -0.52 | -4.57 | - | -5.81 | -5 | -5.64 |
ROE % |
-3.58 | 0.02 | 0.22 | 2.18 | 3.20 | 4.23 | 6.89 | 9.35 | 11.43 | 6.44 | 11.81 | 14.51 | 16.15 | 12.91 | 18.48 | 17.95 | 18.80 | 18.99 | 19.14 | 20.48 | 21.76 | 24.50 | 23.89 | 23.68 | 23.38 | 21.42 | 23.78 | 50.05 | 48.91 | 47.57 | 47.89 | 20.10 | 17.52 | 15.84 | 17.36 | 7.09 | 8.81 | -13.82 | -90.08 | -156.26 | -242.49 | -275.74 | -232.25 | -183.67 | -119.31 | -80.40 | 811.18 | 731.51 | 670.79 | 569.89 | -103.08 | -78.12 | -117.01 |
ROA % |
-2.54 | -0.36 | -0.26 | 1.09 | 1.62 | 2.13 | 3.52 | 4.80 | 5.84 | 3.27 | 5.93 | 7.20 | 8.00 | 6.39 | 9.25 | 9.08 | 9.59 | 9.74 | 9.54 | 9.91 | 10.24 | 11.35 | 11.92 | 12.82 | 13.76 | 13.50 | 14.90 | 31.12 | 30.33 | 29.47 | 28.47 | 10.58 | 8.56 | 7.39 | 6.53 | 2.72 | 3.76 | -7.94 | -30.89 | -50.87 | -77.85 | -83.13 | -77.32 | -69.96 | -55.96 | -49.24 | 117.70 | 113.93 | 110.85 | 100.16 | -18.12 | -13.73 | -20.56 |
ROCE % |
-0.47 | -0.45 | -0.63 | -1.70 | 1.56 | 1.41 | 5.43 | 9.63 | 12.63 | 10.12 | 17.65 | 21.17 | 22.94 | 17.55 | 24.40 | 23.54 | 24.58 | 24.95 | 26.89 | 28.49 | 29.23 | 31.88 | 35.93 | 36.01 | 37.87 | 37.21 | 32.87 | 34.87 | 31.19 | 28.27 | 25.55 | 20.99 | 19.28 | 14.73 | 12.92 | 5.33 | 6.23 | -15.35 | -66.68 | -116.19 | -167.71 | -151.09 | -172.44 | -142.47 | -112.29 | -51.11 | -156.11 | -239.76 | -312.59 | -291.32 | -105.00 | -88.91 | -97.41 |
Current Ratio |
3.5 | 3.6 | 3.5 | 3.5 | 2.0 | 2.1 | 2.0 | 2.0 | 2.0 | 1.9 | 2.1 | 2.0 | 2.0 | 2.0 | 2.0 | 2.0 | 2.0 | 2.0 | 2.0 | 2.0 | 2.0 | 1.9 | 1.9 | 1.9 | 1.9 | 2.7 | 2.7 | 2.7 | 2.7 | 2.6 | 2.6 | 2.6 | 2.6 | 1.9 | 1.9 | 1.9 | 1.9 | 1.4 | 1.4 | 2.1 | 2.1 | 1.4 | 1.4 | 1.4 | 1.4 | 2.6 | 2.6 | 2.6 | 2.6 | 1.2 | 1.2 | 1.2 | 1.2 |
DSO |
92.7 | - | 82.5 | 94.3 | 91.7 | - | 82.9 | 81.3 | 88.0 | - | 83.3 | 85.3 | 93.4 | - | 82.9 | 101.4 | 109.6 | 79.3 | 78.0 | 76.1 | 101.6 | 81.0 | 91.2 | 94.3 | 85.0 | 67.7 | 74.4 | 78.9 | 84.9 | 60.8 | 66.7 | 73.4 | 69.6 | 54.1 | 60.1 | 66.3 | 68.5 | 50.5 | 70.2 | 57.1 | 113.2 | 44.6 | 366.9 | 1641.2 | 1572.0 | 21.4 | 250.7 | - | 28.1 | 139.1 | - | - | - |
DIO |
426.6 | - | 405.1 | 393.1 | 355.3 | - | 296.2 | 387.3 | 444.6 | - | 299.1 | 198.0 | 300.7 | - | 206.2 | 525.8 | 823.6 | - | 504.2 | 600.8 | 647.6 | - | 556.5 | 635.7 | 584.1 | - | 350.0 | 385.3 | 512.2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DPO |
45.8 | - | 18.1 | 34.5 | 43.0 | - | 90.9 | 106.7 | 55.1 | - | 41.3 | 24.0 | 36.9 | - | 26.2 | 66.9 | 179.0 | - | 192.0 | 228.8 | 165.2 | - | 69.3 | 79.2 | 139.7 | - | 146.9 | 161.8 | 230.5 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
519.3 | - | 487.6 | 487.4 | 447.0 | - | 379.1 | 468.6 | 532.6 | - | 382.3 | 283.3 | 394.1 | - | 289.0 | 627.3 | 933.3 | 79.3 | 582.2 | 677.0 | 749.1 | 81.0 | 647.7 | 730.1 | 669.1 | 67.7 | 424.4 | 464.2 | 597.1 | 60.8 | 66.7 | 73.4 | 69.6 | 54.1 | 60.1 | 66.3 | 68.5 | 50.5 | 70.2 | 57.1 | 113.2 | 44.6 | 366.9 | 1641.2 | 1572.0 | 21.4 | 250.7 | - | 28.1 | 139.1 | - | - | - |
Cash Conversion Cycle |
473.5 | - | 469.5 | 452.9 | 404.1 | - | 288.2 | 361.9 | 477.5 | - | 341.1 | 259.3 | 357.1 | - | 262.8 | 560.4 | 754.3 | 79.3 | 390.2 | 448.1 | 584.0 | 81.0 | 578.4 | 650.9 | 529.4 | 67.7 | 277.5 | 302.5 | 366.6 | 60.8 | 66.7 | 73.4 | 69.6 | 54.1 | 60.1 | 66.3 | 68.5 | 50.5 | 70.2 | 57.1 | 113.2 | 44.6 | 366.9 | 1641.2 | 1572.0 | 21.4 | 250.7 | - | 28.1 | 139.1 | - | - | - |
All numbers in USD currency